Base on the BMO reported, which gave PFE an OUTPERFORM rating and a $60 price target based on 7.4 times estimated earnings for the next 12 months which is much better than MRK and most other large pharmas. It talked about COVID revenues as well as a well diversified approved drug portfolio. It also stressed a solid pipeline. So PFE still has more room to move up. Hold tight guys, still have profit in it.
精彩评论